Temsirolimus News and Research

RSS
Temsirolimus is approved by the Food and Drug Administration (FDA) to treat advanced renal cell carcinoma (kidney cancer). Temsirolimus is also being studied in the treatment of other types of cancer. Temsirolimus is an ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.
New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

New treatment modalities for RCC

New treatment modalities for RCC

Surgery still the only measure to cure RCC

Surgery still the only measure to cure RCC

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

NICE leaves many patients with rarer forms of cancer without drugs

NICE leaves many patients with rarer forms of cancer without drugs

FDA approves new oral medication for renal cell carcinoma

FDA approves new oral medication for renal cell carcinoma

Memorial Sloan-Kettering Cancer Center awards $50,000 to three young investigators

Memorial Sloan-Kettering Cancer Center awards $50,000 to three young investigators

Winners of Paul Marks Prize 2009

Winners of Paul Marks Prize 2009

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Combination of temsirolimus and bryostatin appears safe and active in metastatic kidney cancer

Combination of temsirolimus and bryostatin appears safe and active in metastatic kidney cancer

UK kidney cancer patients face toxic, out-dated treatments with little hope of change

UK kidney cancer patients face toxic, out-dated treatments with little hope of change

Wyeth receives European approval for TORISEL

Wyeth receives European approval for TORISEL

Cancer trial combines multiple drugs to attack blood vessel formation in patients with kidney cancer

Cancer trial combines multiple drugs to attack blood vessel formation in patients with kidney cancer

New pathway for inflammation-induced cancer

New pathway for inflammation-induced cancer

FDA approves Torisel (temsirolimus) for advanced kidney cancer

FDA approves Torisel (temsirolimus) for advanced kidney cancer

Temsirolimus, effective new treatment for advanced renal cell carcinoma

Temsirolimus, effective new treatment for advanced renal cell carcinoma

FDA fast tracks temsirolimus, first-line treatment of poor-prognosis patients with advanced renal cell carcinoma

FDA fast tracks temsirolimus, first-line treatment of poor-prognosis patients with advanced renal cell carcinoma